Cargando…

A novel microbial and hepatic biotransformation-integrated network pharmacology strategy explores the therapeutic mechanisms of bioactive herbal products in neurological diseases: the effects of Astragaloside IV on intracerebral hemorrhage as an example

BACKGROUND: The oral bioavailability and blood–brain barrier permeability of many herbal products are too low to explain the significant efficacy fully. Gut microbiota and liver can metabolize herbal ingredients to more absorbable forms. The current study aims to evaluate the ability of a novel biot...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, En, Li, Zhilin, Li, Teng, Yang, Xueping, Ding, Ruoqi, Jiang, Haoying, Su, Hong, Cheng, Menghan, Yu, Zhe, Li, Haigang, Tang, Tao, Wang, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108474/
https://www.ncbi.nlm.nih.gov/pubmed/37069580
http://dx.doi.org/10.1186/s13020-023-00745-5
_version_ 1785026855627128832
author Hu, En
Li, Zhilin
Li, Teng
Yang, Xueping
Ding, Ruoqi
Jiang, Haoying
Su, Hong
Cheng, Menghan
Yu, Zhe
Li, Haigang
Tang, Tao
Wang, Yang
author_facet Hu, En
Li, Zhilin
Li, Teng
Yang, Xueping
Ding, Ruoqi
Jiang, Haoying
Su, Hong
Cheng, Menghan
Yu, Zhe
Li, Haigang
Tang, Tao
Wang, Yang
author_sort Hu, En
collection PubMed
description BACKGROUND: The oral bioavailability and blood–brain barrier permeability of many herbal products are too low to explain the significant efficacy fully. Gut microbiota and liver can metabolize herbal ingredients to more absorbable forms. The current study aims to evaluate the ability of a novel biotransformation-integrated network pharmacology strategy to discover the therapeutic mechanisms of low-bioavailability herbal products in neurological diseases. METHODS: A study on the mechanisms of Astragaloside IV (ASIV) in treating intracerebral hemorrhage (ICH) was selected as an example. Firstly, the absorbed ASIV metabolites were collected by a literature search. Next, the ADMET properties and the ICH-associated targets of ASIV and its metabolites were compared. Finally, the biotransformation-increased targets and biological processes were screened out and verified by molecular docking, molecular dynamics simulation, and cell and animal experiments. RESULTS: The metabolites (3-epi-cycloastragenol and cycloastragenol) showed higher bioavailability and blood–brain barrier permeability than ASIV. Biotransformation added the targets ASIV in ICH, including PTK2, CDC42, CSF1R, and TNF. The increased targets were primarily enriched in microglia and involved in cell migration, proliferation, and inflammation. The computer simulations revealed that 3-epi-cycloastragenol bound CSF1R and cycloastragenol bound PTK2 and CDC42 stably. The In vivo and in vitro studies confirmed that the ASIV-derived metabolites suppressed CDC42 and CSF1R expression and inhibited microglia migration, proliferation, and TNF-α secretion. CONCLUSION: ASIV inhibits post-ICH microglia/macrophage proliferation and migration, probably through its transformed products to bind CDC42, PTK2, and CSF1R. The integrated strategy can be used to discover novel mechanisms of herbal products or traditional Chinses medicine in treating diseases. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13020-023-00745-5.
format Online
Article
Text
id pubmed-10108474
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101084742023-04-18 A novel microbial and hepatic biotransformation-integrated network pharmacology strategy explores the therapeutic mechanisms of bioactive herbal products in neurological diseases: the effects of Astragaloside IV on intracerebral hemorrhage as an example Hu, En Li, Zhilin Li, Teng Yang, Xueping Ding, Ruoqi Jiang, Haoying Su, Hong Cheng, Menghan Yu, Zhe Li, Haigang Tang, Tao Wang, Yang Chin Med Research BACKGROUND: The oral bioavailability and blood–brain barrier permeability of many herbal products are too low to explain the significant efficacy fully. Gut microbiota and liver can metabolize herbal ingredients to more absorbable forms. The current study aims to evaluate the ability of a novel biotransformation-integrated network pharmacology strategy to discover the therapeutic mechanisms of low-bioavailability herbal products in neurological diseases. METHODS: A study on the mechanisms of Astragaloside IV (ASIV) in treating intracerebral hemorrhage (ICH) was selected as an example. Firstly, the absorbed ASIV metabolites were collected by a literature search. Next, the ADMET properties and the ICH-associated targets of ASIV and its metabolites were compared. Finally, the biotransformation-increased targets and biological processes were screened out and verified by molecular docking, molecular dynamics simulation, and cell and animal experiments. RESULTS: The metabolites (3-epi-cycloastragenol and cycloastragenol) showed higher bioavailability and blood–brain barrier permeability than ASIV. Biotransformation added the targets ASIV in ICH, including PTK2, CDC42, CSF1R, and TNF. The increased targets were primarily enriched in microglia and involved in cell migration, proliferation, and inflammation. The computer simulations revealed that 3-epi-cycloastragenol bound CSF1R and cycloastragenol bound PTK2 and CDC42 stably. The In vivo and in vitro studies confirmed that the ASIV-derived metabolites suppressed CDC42 and CSF1R expression and inhibited microglia migration, proliferation, and TNF-α secretion. CONCLUSION: ASIV inhibits post-ICH microglia/macrophage proliferation and migration, probably through its transformed products to bind CDC42, PTK2, and CSF1R. The integrated strategy can be used to discover novel mechanisms of herbal products or traditional Chinses medicine in treating diseases. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13020-023-00745-5. BioMed Central 2023-04-17 /pmc/articles/PMC10108474/ /pubmed/37069580 http://dx.doi.org/10.1186/s13020-023-00745-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Hu, En
Li, Zhilin
Li, Teng
Yang, Xueping
Ding, Ruoqi
Jiang, Haoying
Su, Hong
Cheng, Menghan
Yu, Zhe
Li, Haigang
Tang, Tao
Wang, Yang
A novel microbial and hepatic biotransformation-integrated network pharmacology strategy explores the therapeutic mechanisms of bioactive herbal products in neurological diseases: the effects of Astragaloside IV on intracerebral hemorrhage as an example
title A novel microbial and hepatic biotransformation-integrated network pharmacology strategy explores the therapeutic mechanisms of bioactive herbal products in neurological diseases: the effects of Astragaloside IV on intracerebral hemorrhage as an example
title_full A novel microbial and hepatic biotransformation-integrated network pharmacology strategy explores the therapeutic mechanisms of bioactive herbal products in neurological diseases: the effects of Astragaloside IV on intracerebral hemorrhage as an example
title_fullStr A novel microbial and hepatic biotransformation-integrated network pharmacology strategy explores the therapeutic mechanisms of bioactive herbal products in neurological diseases: the effects of Astragaloside IV on intracerebral hemorrhage as an example
title_full_unstemmed A novel microbial and hepatic biotransformation-integrated network pharmacology strategy explores the therapeutic mechanisms of bioactive herbal products in neurological diseases: the effects of Astragaloside IV on intracerebral hemorrhage as an example
title_short A novel microbial and hepatic biotransformation-integrated network pharmacology strategy explores the therapeutic mechanisms of bioactive herbal products in neurological diseases: the effects of Astragaloside IV on intracerebral hemorrhage as an example
title_sort novel microbial and hepatic biotransformation-integrated network pharmacology strategy explores the therapeutic mechanisms of bioactive herbal products in neurological diseases: the effects of astragaloside iv on intracerebral hemorrhage as an example
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108474/
https://www.ncbi.nlm.nih.gov/pubmed/37069580
http://dx.doi.org/10.1186/s13020-023-00745-5
work_keys_str_mv AT huen anovelmicrobialandhepaticbiotransformationintegratednetworkpharmacologystrategyexploresthetherapeuticmechanismsofbioactiveherbalproductsinneurologicaldiseasestheeffectsofastragalosideivonintracerebralhemorrhageasanexample
AT lizhilin anovelmicrobialandhepaticbiotransformationintegratednetworkpharmacologystrategyexploresthetherapeuticmechanismsofbioactiveherbalproductsinneurologicaldiseasestheeffectsofastragalosideivonintracerebralhemorrhageasanexample
AT liteng anovelmicrobialandhepaticbiotransformationintegratednetworkpharmacologystrategyexploresthetherapeuticmechanismsofbioactiveherbalproductsinneurologicaldiseasestheeffectsofastragalosideivonintracerebralhemorrhageasanexample
AT yangxueping anovelmicrobialandhepaticbiotransformationintegratednetworkpharmacologystrategyexploresthetherapeuticmechanismsofbioactiveherbalproductsinneurologicaldiseasestheeffectsofastragalosideivonintracerebralhemorrhageasanexample
AT dingruoqi anovelmicrobialandhepaticbiotransformationintegratednetworkpharmacologystrategyexploresthetherapeuticmechanismsofbioactiveherbalproductsinneurologicaldiseasestheeffectsofastragalosideivonintracerebralhemorrhageasanexample
AT jianghaoying anovelmicrobialandhepaticbiotransformationintegratednetworkpharmacologystrategyexploresthetherapeuticmechanismsofbioactiveherbalproductsinneurologicaldiseasestheeffectsofastragalosideivonintracerebralhemorrhageasanexample
AT suhong anovelmicrobialandhepaticbiotransformationintegratednetworkpharmacologystrategyexploresthetherapeuticmechanismsofbioactiveherbalproductsinneurologicaldiseasestheeffectsofastragalosideivonintracerebralhemorrhageasanexample
AT chengmenghan anovelmicrobialandhepaticbiotransformationintegratednetworkpharmacologystrategyexploresthetherapeuticmechanismsofbioactiveherbalproductsinneurologicaldiseasestheeffectsofastragalosideivonintracerebralhemorrhageasanexample
AT yuzhe anovelmicrobialandhepaticbiotransformationintegratednetworkpharmacologystrategyexploresthetherapeuticmechanismsofbioactiveherbalproductsinneurologicaldiseasestheeffectsofastragalosideivonintracerebralhemorrhageasanexample
AT lihaigang anovelmicrobialandhepaticbiotransformationintegratednetworkpharmacologystrategyexploresthetherapeuticmechanismsofbioactiveherbalproductsinneurologicaldiseasestheeffectsofastragalosideivonintracerebralhemorrhageasanexample
AT tangtao anovelmicrobialandhepaticbiotransformationintegratednetworkpharmacologystrategyexploresthetherapeuticmechanismsofbioactiveherbalproductsinneurologicaldiseasestheeffectsofastragalosideivonintracerebralhemorrhageasanexample
AT wangyang anovelmicrobialandhepaticbiotransformationintegratednetworkpharmacologystrategyexploresthetherapeuticmechanismsofbioactiveherbalproductsinneurologicaldiseasestheeffectsofastragalosideivonintracerebralhemorrhageasanexample
AT huen novelmicrobialandhepaticbiotransformationintegratednetworkpharmacologystrategyexploresthetherapeuticmechanismsofbioactiveherbalproductsinneurologicaldiseasestheeffectsofastragalosideivonintracerebralhemorrhageasanexample
AT lizhilin novelmicrobialandhepaticbiotransformationintegratednetworkpharmacologystrategyexploresthetherapeuticmechanismsofbioactiveherbalproductsinneurologicaldiseasestheeffectsofastragalosideivonintracerebralhemorrhageasanexample
AT liteng novelmicrobialandhepaticbiotransformationintegratednetworkpharmacologystrategyexploresthetherapeuticmechanismsofbioactiveherbalproductsinneurologicaldiseasestheeffectsofastragalosideivonintracerebralhemorrhageasanexample
AT yangxueping novelmicrobialandhepaticbiotransformationintegratednetworkpharmacologystrategyexploresthetherapeuticmechanismsofbioactiveherbalproductsinneurologicaldiseasestheeffectsofastragalosideivonintracerebralhemorrhageasanexample
AT dingruoqi novelmicrobialandhepaticbiotransformationintegratednetworkpharmacologystrategyexploresthetherapeuticmechanismsofbioactiveherbalproductsinneurologicaldiseasestheeffectsofastragalosideivonintracerebralhemorrhageasanexample
AT jianghaoying novelmicrobialandhepaticbiotransformationintegratednetworkpharmacologystrategyexploresthetherapeuticmechanismsofbioactiveherbalproductsinneurologicaldiseasestheeffectsofastragalosideivonintracerebralhemorrhageasanexample
AT suhong novelmicrobialandhepaticbiotransformationintegratednetworkpharmacologystrategyexploresthetherapeuticmechanismsofbioactiveherbalproductsinneurologicaldiseasestheeffectsofastragalosideivonintracerebralhemorrhageasanexample
AT chengmenghan novelmicrobialandhepaticbiotransformationintegratednetworkpharmacologystrategyexploresthetherapeuticmechanismsofbioactiveherbalproductsinneurologicaldiseasestheeffectsofastragalosideivonintracerebralhemorrhageasanexample
AT yuzhe novelmicrobialandhepaticbiotransformationintegratednetworkpharmacologystrategyexploresthetherapeuticmechanismsofbioactiveherbalproductsinneurologicaldiseasestheeffectsofastragalosideivonintracerebralhemorrhageasanexample
AT lihaigang novelmicrobialandhepaticbiotransformationintegratednetworkpharmacologystrategyexploresthetherapeuticmechanismsofbioactiveherbalproductsinneurologicaldiseasestheeffectsofastragalosideivonintracerebralhemorrhageasanexample
AT tangtao novelmicrobialandhepaticbiotransformationintegratednetworkpharmacologystrategyexploresthetherapeuticmechanismsofbioactiveherbalproductsinneurologicaldiseasestheeffectsofastragalosideivonintracerebralhemorrhageasanexample
AT wangyang novelmicrobialandhepaticbiotransformationintegratednetworkpharmacologystrategyexploresthetherapeuticmechanismsofbioactiveherbalproductsinneurologicaldiseasestheeffectsofastragalosideivonintracerebralhemorrhageasanexample